ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Metrics to compare | 0RQE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship0RQEPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.0x | −3.4x | −0.6x | |
PEG Ratio | 0.01 | −0.10 | 0.00 | |
Price/Book | −0.5x | 2.3x | 2.6x | |
Price / LTM Sales | 2.5x | 8.0x | 3.3x | |
Upside (Analyst Target) | - | 135.8% | 40.1% | |
Fair Value Upside | Unlock | 7.4% | 5.3% | Unlock |